It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Transmembrane AMPA receptor regulatory proteins (TARPs) and germ cell-specific gene 1-like protein (GSG1L) are claudin-type AMPA receptor (AMPAR) auxiliary subunits that profoundly regulate glutamatergic synapse strength and plasticity. While AMPAR-TARP complexes have been extensively studied, less is known about GSG1L-containing AMPARs. Here, we show that GSG1L’s spatiotemporal expression, native interactome and allosteric sites are distinct. GSG1L generally expresses late during brain development in a region-specific manner, constituting about 5% of all AMPAR complexes in adulthood. While GSG1L can co-assemble with TARPs or cornichons (CNIHs), it also assembles as the sole auxiliary subunit. Unexpectedly, GSG1L acts through two discrete evolutionarily-conserved sites on the agonist-binding domain with a weak allosteric interaction at the TARP/KGK site to slow desensitization, and a stronger interaction at a different site that slows recovery from desensitization. Together, these distinctions help explain GSG1L’s evolutionary past and how it fulfills a unique signaling role within glutamatergic synapses.
TARPs and GSG1L are evolutionarily- and structurally-related AMPA receptor auxiliary subunits that differ in function through unresolved mechanisms. Here, the authors provide insight into the spatiotemporal expression, composition, and functionality of GSG1L-containing protein complexes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 McGill University, Integrated Program in Neuroscience, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); McGill University, Department of Pharmacology and Therapeutics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
2 University of Freiburg, Institute of Physiology, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203)
3 Vanderbilt University School of Medicine, Department of Molecular Physiology and Biophysics, Vanderbilt Brain Institute, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
4 Vanderbilt University School of Medicine, Department of Molecular Physiology and Biophysics, Vanderbilt Brain Institute, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217); Vanderbilt University School of Medicine, Center for Structural Biology, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
5 University of Freiburg, Institute of Physiology, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); University of Freiburg, Schänzlestr. 18, Signaling Research Centers BIOSS and CIBSS, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203)
6 McGill University, Department of Pharmacology and Therapeutics, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)